Phase 2
Completed N=10
Abatacept in the Treatment of Uveitis
Source: ClinicalTrials.gov NCT01279954 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcomePrimary: Adverse Events — 0; 0; 0 Participants
Summary
The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adverse Events |
0; 0; 0 | — |
| SECONDARY Number of Participants With Improvement by 2 or More Lines of Best-corrected Visual Acuity |
— | — |
| SECONDARY Number of Participants With Reduction in Systemic Corticosteroid or Other Immunosuppressive Therapy by at Least 50% |
6 | — |
| SECONDARY Number of Participants With Control of Ocular Inflammation, as Judged on Clinical Criteria, According to Standard Methods |
4 | — |
Eligibility Criteria
Inclusion Criteria
- patients with vision-threatening autoimmune uveitis
- failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects
Exclusion Criteria
- serious concomitant illness that could interfere with the subject's participation
Data sourced from ClinicalTrials.gov (NCT01279954). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.